DRTS
Alpha Tau Medical Ltd
$
3.000
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.000
Open
3.000
VWAP
3.00
Vol
1.01K
Mkt Cap
254.10M
Low
3.000
Amount
3.03K
EV/EBITDA(TTM)
--
Total Shares
69.80M
EV
268.98M
EV/OCF(TTM)
--
P/S(TTM)
--
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.123
-5.13%
--
--
-0.110
+10%
--
--
-0.117
+6.06%
Estimates Revision
The market is revising No Change the revenue expectations for Alpha Tau Medical Ltd. (DRTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 9.49%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-3.31%
In Past 3 Month
Stock Price
Go Up
+9.49%
In Past 3 Month
3 Analyst Rating
144.33% Upside
Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
144.33% Upside
Current: 3.000
Low
5.00
Averages
7.33
High
9.00
144.33% Upside
Current: 3.000
Low
5.00
Averages
7.33
High
9.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2025-04-29
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2025-04-29
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2025-03-17
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-11-22
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-11-22
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-10-23
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-10-23
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-10-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-10-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-08-20
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-08-20
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Alpha Tau Medical Ltd (DRTS.O) is -5.66, compared to its 5-year average forward P/E of -13.79. For a more detailed relative valuation and DCF analysis to assess Alpha Tau Medical Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-13.79
Current PE
-5.66
Overvalued PE
-1.57
Undervalued PE
-26.02
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.90
Current EV/EBITDA
-4.62
Overvalued EV/EBITDA
0.28
Undervalued EV/EBITDA
-8.08
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
304.48
Current PS
771.16
Overvalued PS
959.49
Undervalued PS
-350.53
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
N/A
Operating Profit
FY2025Q1
YoY :
+8.90%
-8.69M
Net Income after Tax
FY2025Q1
YoY :
+9.09%
-0.12
EPS - Diluted
FY2022Q2
YoY :
+221.47%
-9.12M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DRTS News & Events
Events Timeline
2025-05-19 (ET)
2025-05-19
16:03:19
Alpha Tau reports Q1 EPS (12c), consensus (13c)
2025-04-28 (ET)
2025-04-28
09:05:26
Alpha Tau enters strategic marketing alliance with Oramed
2025-04-28
09:04:22
Oramed announces $36.9M investment and collaboration with Alpha Tau
Sign Up For More Events
Sign Up For More Events
News
9.5
05-19NewsfilterAlpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
1.0
05-06NewsfilterAlpha Tau to Participate in May Investor Conferences
8.5
04-28NewsfilterOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Sign Up For More News
People Also Watch
LNKB
LINKBANCORP Inc
6.850
USD
0.00%
FVR
FrontView REIT Inc
11.240
USD
0.00%
OSUR
OraSure Technologies Inc
2.519
USD
-1.79%
WTI
W&T Offshore Inc
1.385
USD
+0.36%
INVZ
Innoviz Technologies Ltd
0.853
USD
-5.01%
JMSB
John Marshall Bancorp Inc
17.375
USD
0.00%
NREF
Nexpoint Real Estate Finance Inc
14.920
USD
0.00%
BYON
Beyond Inc
5.655
USD
-4.15%
CPS
Cooper-Standard Holdings Inc
21.740
USD
-1.81%
TG
Tredegar Corp
8.190
USD
0.00%
FAQ
What is Alpha Tau Medical Ltd (DRTS) stock price today?
The current price of DRTS is 3 USD — it has increased 0 % in the last trading day.
What is Alpha Tau Medical Ltd (DRTS)'s business?
What is the price predicton of DRTS Stock?
What is Alpha Tau Medical Ltd (DRTS)'s revenue for the last quarter?
What is Alpha Tau Medical Ltd (DRTS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Alpha Tau Medical Ltd (DRTS)'s fundamentals?
How many employees does Alpha Tau Medical Ltd (DRTS). have?